- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
The Financial Post published a profile of Miraculins Inc. (TSXV:MOM), a medical device company focused on developing and marketing its Scout DS® diabetes screening technology.
As quoted in the market news:
The economic argument for early diabetes screening is compelling. As prediabetes progresses to diabetes, the incremental costs rise to an average of $37,000 per patient per year. This progression can be slowed or even thwarted by lifestyle and dietary changes. Unchecked, complications from diabetes can include blindness, heart disease, stroke, kidney disease, nerve damage, erectile dysfunction, amputation, and death.
Moreau commented:
Diabetes is the world’s fastest growing disease. The Scout DS® technology is positioned to make a significant impact on screening for pre-diabetes and type 2 diabetes. Our device is mobile and doesn’t require needles, blood draw, fasting or waiting. You just put your arm on it, the test operator initiates the scan and measurement, and you receive your results in under 90 seconds.
Part of the function of the Scout DS® risk assessment is to get to the right people – those most vulnerable to diabetes based on age or a combination of age and risk factors – and motivate them to see their healthcare provider to get a full diagnostic test.
Click here to read the full Financial Post article.
Click here to view the Miraculins Inc. (TSXV:MOM) profile.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.